NCT05314933View on ClinicalTrials.gov

Safety and Pharmacokinetic Study of Intranasal 2-DG in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

45

Participants

Timeline

Start Date

March 3, 2022

Primary Completion Date

August 1, 2023

Study Completion Date

September 27, 2023

Conditions

Acute Nasopharyngitis

Interventions

DRUG

2-Deoxyglucose

Intranasal administration

OTHER

Placebo

Intranasal administration

Trial Locations (1)

1090

Medical University of Vienna, Vienna

All Listed Sponsors

lead

G.ST Antivirals GmbH

INDUSTRY